{"entity":{"id":"nct07775287","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","aka":[],"tldr":"A phase 3 trial of Petosemtamab, Cetuximab, Bevacizumab in colorectal cancer, run by Genmab, now recruiting.","summary":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) is a phase 3 interventional study registered as NCT07775287 by Genmab, with 600 participants planned, started 2026-09-15 and due to reach its primary completion in 2029-03-30. Interventions recorded: Petosemtamab, Cetuximab, Bevacizumab, 5-FU, Leucovorin (Calcium Folinate). Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07775287","url":"https://clinicaltrials.gov/study/NCT07775287"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["antiangiogenic","bispecific-antibody","monoclonal-antibody"],"targets":[],"drugs":["petosemtamab","cetuximab","bevacizumab","flot","fluorouracil","leucovorin"],"companies":["genmab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07775287","phase":"3","setting":"A Randomized, Open-label, Phase 3 Trial of Petosemtamab + FOLFIRI/mFOLFOX6 Versus Cetuximab or Bevacizumab + FOLFIRI/mFOLFOX6 as Second-line Treatment in Participants With RAS and BRAF Wild-type, Recurrent, Unresectable or Metastatic Colorectal Cancer","sponsor":"Genmab","participation":[{"nct":"NCT07775287","source":"https://clinicaltrials.gov/study/NCT07775287","fetchedAt":"2026-10-07T16:56:51.027Z","studySha256":"ae44e7cc03336ad5eec8091bde49e435b69bfc7d6c07b255d438230359ca915b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Genmab","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":600,"enrolmentType":"ESTIMATED","siteCount":4,"recruitingSiteCount":4,"countries":["Puerto Rico","United States"]}],"started":"2026-09-15","startedType":"estimated","enrolled":600,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07775287/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/"}],"company":[{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"}]}}